<SEC-DOCUMENT>0001104659-26-002496.txt : 20260109
<SEC-HEADER>0001104659-26-002496.hdr.sgml : 20260109
<ACCEPTANCE-DATETIME>20260109163055
ACCESSION NUMBER:		0001104659-26-002496
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20260109
DATE AS OF CHANGE:		20260109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HYPERION DEFI, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288776
		FILM NUMBER:		26523427

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		833-393-6684

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYENOVIA, INC.
		DATE OF NAME CHANGE:	20160818
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tm2521045d6_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)<BR>
Registration No. 333-288776</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2521045d6_424b3img001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 50,770,667 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This prospectus relates
to the offer and sale from time to time, by the selling securityholders identified in this prospectus, of up to 50,770,667 shares of common
stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), of Hyperion DeFi,&nbsp;Inc., formerly known as Eyenovia,&nbsp;Inc.
(&ldquo;Hyperion DeFi&rdquo; or the &ldquo;Company&rdquo;) which includes (i)&nbsp;up to 15,384,615 shares of Common Stock issuable upon
the conversion of 5,128,205 shares of the Company&rsquo;s Series&nbsp;A Non-Voting Preferred Stock, par value $0.0001 per share (the &ldquo;Series&nbsp;A
Preferred Stock&rdquo;), that were issued pursuant to the Securities Purchase Agreement, dated June&nbsp;17, 2025, by and among the Company
and certain institutional accredited investors (the &ldquo;Securities Purchase Agreement&rdquo;); (ii)&nbsp;up to 30,769,230 shares of
Common Stock issuable upon the exercise of warrants (the &ldquo;Purchaser Warrants&rdquo;) at an exercise price of $3.25 per share, which
Purchaser Warrants were issued pursuant to the Securities Purchase Agreement; (iii)&nbsp;up to 923,076 shares of Common Stock issuable
upon the conversion of 307,692 shares of Series&nbsp;A Preferred Stock that were issued pursuant to the Engagement Letter, dated June&nbsp;17,
2025, by and between the Company and Chardan Capital Markets, LLC (the &ldquo;Engagement Letter&rdquo;); (iv)&nbsp;up to 1,846,153 shares
of Common Stock issuable upon the exercise of warrants (the &ldquo;Placement Agent Warrants&rdquo;) at an exercise price of $3.25 per
share, which Placement Agent Warrants were issued pursuant to the Engagement Letter; (v)&nbsp;up to 1,497,593 shares of Common Stock issuable
as in-kind dividends on the Series&nbsp;A Preferred Stock; and (vi)&nbsp;up to </FONT><FONT STYLE="color: #212529; background-color: white">350,000</FONT>
shares of Common Stock issuable upon the exercise of warrants (the &ldquo;Lender Warrants&rdquo; and, together with the Purchaser Warrants
and the Placement Agent Warrants, the &ldquo;Warrants&rdquo;) at an exercise price of $4.00 per share, which Lender Warrants were issued
in connection with the Fourth Amendment (the &ldquo;Fourth Amendment&rdquo;) to the Supplement (the &ldquo;Supplement&rdquo;) to that
certain Loan and Security Agreement, dated November&nbsp;22, 2022 (the &ldquo;Loan and Security Agreement&rdquo;) with Avenue Capital
Management II, L.P., as administrative agent and collateral agent, Avenue Venture Opportunities Fund, L.P., as a lender (&ldquo;Avenue
I&rdquo;) and Avenue Venture Opportunities Fund II, L.P., as a lender (&ldquo;Avenue II&rdquo; and, together with Avenue I, the &ldquo;Lenders&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Common Stock may be offered and sold from
time to time by the entities or individuals listed in the section titled &ldquo;Selling Securityholders&rdquo; beginning on page&nbsp;14
(the &ldquo;Selling Securityholders&rdquo;). We are registering these securities for sale by the Selling Securityholders to satisfy certain
registration rights that we have granted to the Selling Securityholders. We are not selling any securities under this prospectus and
will not receive any of the proceeds from the sale of securities by the Selling Securityholders. We will pay the expenses incurred in
registering the Common Stock covered by the prospectus, including legal and accounting fees. The Selling Securityholders will bear all
commissions and discounts, if any, attributable to its respective sales of Common Stock under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Securityholders may sell the Common
Stock described in this prospectus in a number of different ways and at varying prices. We provide more information about how a Selling
Securityholder may sell its Common Stock in the section titled &ldquo;Plan of Distribution&rdquo; on page&nbsp;17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;HYPD.&rdquo; On January 8</FONT>, 2026, the last reported
sale price of our Common Stock was $3.45 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a &ldquo;smaller reporting company&rdquo;
under applicable Securities and Exchange Commission rules&nbsp;and are subject to reduced public company reporting requirements for this
prospectus and future filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our securities involves a high
degree of risk. Before buying our securities, you should carefully consider the risks described under the caption &ldquo;Risk Factors&rdquo;
beginning on page&nbsp;9 of this prospectus and in the documents incorporated by reference into this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;January&nbsp;9,
2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: right"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_002">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_003">THE OFFERING</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_003">8</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_004">RISK FACTORS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_005">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006">USE OF PROCEEDS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_007">SELLING SECURITYHOLDERS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_009">LEGAL MATTERS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010">EXPERTS</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_011">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_012">INCORPORATION BY REFERENCE</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration statement
that we filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), under which the Selling Securityholders may, from
time to time, sell the securities described in this prospectus in one or more offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither we nor the Selling Securityholders have
authorized anyone to provide you with information that is different from or in addition to the information contained or incorporated by
reference in this prospectus. Accordingly, neither we nor any Selling Securityholder takes any responsibility for, or can provide any
assurance as to the reliability of, any information that others may give. The Selling Securityholders are offering to sell, and seeking
offers to buy, our securities only in jurisdictions where it is lawful to do so. This prospectus does not constitute an offer to sell
or the solicitation of an offer to buy any securities other than where offers and sales of these securities are permitted or an offer
to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You
should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus and that any information
we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of
delivery of this prospectus, or any sale of our securities. Our business, financial condition, results of operations and prospects may
have changed materially since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In making your investment decision it is important
for you to read and consider all information contained in this prospectus. You should also read and consider the information in the documents
to which we have referred you in the section titled &ldquo;Incorporation by Reference&rdquo; in this prospectus. To the extent the information
contained in this prospectus differs or varies from the information contained in documents previously filed with the SEC that are incorporated
by reference herein, the information in this prospectus will supersede such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All brand names or trademarks appearing in this
prospectus are the property of their respective holders. Use or display by us of other parties&rsquo; trademarks, trade dress, or products
in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark
or trade dress owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All references in this prospectus to &ldquo;Hyperion
DeFi,&rdquo; &ldquo;HYPD,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; or similar references,
refer to Hyperion DeFi,&nbsp;Inc., except where the context otherwise requires or as otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 0.25in; padding-left: 0.25in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary highlights selected information
included or incorporated by reference in this prospectus and does not contain all of the information that may be important to you. You
should carefully review this entire prospectus, including the risk factors and financial statements and related notes thereto included
or incorporated by reference herein, before making a decision to purchase our securities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hyperion DeFi, Inc. is the first U.S. publicly
listed company building a long-term strategic treasury of Hyperliquid&rsquo;s native token, HYPE, in addition to being a pioneering digital
ophthalmic technology company. Hyperion DeFi is working to provide its shareholders with simplified exposure to the Hyperliquid ecosystem,
which we believe to be one of the highest revenue-generating blockchains in the world, according to information provided by various blockchain
data tracking sources, including Artemis Analytics and DefiLlama. At the same time, we continue to execute on our planned completion
of development and registration of our Optejet ophthalmic liquid delivery device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HYPE Treasury</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hyperliquid is a layer one (L1) blockchain
engineered for transparent high-frequency finance. The blockchain hosts fully on-chain perpetual futures and spot order books, with every
order, cancel, trade and liquidation occurring within 70 millisecond block times and offering up to 200,000 transactions per second,
resulting in near-instant trade settlement. The Hyperliquid blockchain also hosts the HyperEVM, a general-purpose smart contract platform
that, like Ethereum, supports permissionless decentralized financial applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hyperliquid supports non-custodial trading
via its performant HyperCore order books, with perpetual futures trading for a range of digital assets with Bitcoin (BTC), Ether (ETH),
Ripple (XRP), Solana (SOL) and Sui (SUI) driving its utilization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Perpetual futures are a type of cryptocurrency derivative contract
that allows traders to speculate on the price of an asset without owning the underlying asset itself. Unlike traditional futures contracts,
perpetual futures have no expiration date, allowing traders to hold positions indefinitely, as long as they meet margin requirements.
Hyperliquid utilizes a traditional order book system. This approach allows traders to place bids and asks for various assets, more akin
to a centralized cryptocurrency exchange than other decentralized exchanges that rely on automated market makers to fulfill orders. The
Hyperliquid blockchain is available to any potential user with a compatible cryptocurrency wallet such as MetaMask, Phantom, and Coinbase
Wallet. However, Hyperliquid interface operators can choose to block persons in certain jurisdictions or sanctioned wallets as required
via solutions such as geoblocking and address screening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">HYPE is the native token
of Hyperliquid. The total supply of HYPE is 1 billion, with 31% of the supply issued in November 2024. 38.88% of the total supply is
reserved for future community emissions. HYPE serves multiple purposes: users can stake HYPE to reduce their trading fees, use it to
conduct transactions on the HyperEVM, and use it as collateral on various DeFi applications. In addition, Hyperliquid has a unique
network mechanism that autonomously purchases and removes HYPE tokens from circulation. This is done by using the trading fees generated
on the network&rsquo;s order books to buy back available HYPE: approximately 99% of daily fees are allocated to this mechanism, which
serves as a consistent &ldquo;marginal buyer&rdquo; for the token. As of November 2025, more than 35 million HYPE have been removed from
circulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Hyperliquid L1 is a proof-of-stake blockchain, in which validators that have staked the threshold number of HYPE tokens are selected
to produce blocks, and will receive rewards when they successfully validate blocks. Holders of HYPE can delegate to validators who
then are able to vote on certain decisions regarding the platform, such as the listing and de-listing of new markets. Any holder of
HYPE can delegate HYPE to a validator to earn staking rewards, should the validator successfully participate in network consensus.
Staked HYPE is locked until un-staked, and subject to a seven-day un-staking queue before HYPE is released back to the user. Staking
also provides revenues to the Company in the form of staking yields; however, the required seven-day unlocking period may limit the
Company&rsquo;s liquidity while its HYPE remains staked. The Company anticipates operating with sufficient cash and cash equivalents
to cover its expenses and any debt obligations during these periods. In addition, all HiHYPE owned by the Company (as described
further below), and other future liquid staking HYPE which may potentially be owned by the Company, will be subject to the same
seven-day unlocking period. The Company initialized the staking process on July 1, 2025, and as of September 30, 2025, it had
approximately 834,050.16 HYPE staked directly to the Kinetiq x Hyperion validator, described further below.</FONT> The Company
intends for staking to become a primary revenue generation strategy in the coming fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Metrics of Hyperliquid and HYPE as
of October 31, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">One
                                            of the highest revenue generating blockchain cryptocurrencies; ranked #11 market cap (excluding
                                            stablecoins)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Hyperliquid
                                            generates annual revenue of approximately $1.3 billion, based on an October 2025 observed
                                            run-rate of $3-$3.5 million per day. In addition, platforms built on Hyperliquid earn approximately
                                            $2 million in fees per day, bringing the total to $5 million per day across the blockchain
                                            and platforms</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Approximately
                                            99% of Hyperliquid revenues are used by the Hyperliquid Assistance Fund, which has cumulatively
                                            purchased and owns 34.25 million HYPE tokens with a market value of $1.45 billion</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There
                                            have been over 800,000 cumulative Hyperliquid marketplace users since inception</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">The
                                            Hyperliquid Token&rsquo;s maximum supply is 1 billion, of which the circulating supply is
                                            337 million, corresponding to a market capitalization outstanding of approximately $14.3
                                            billion</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Daily
                                            trading volume on Hyperliquid exceeds $12 billion</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cumulative
                                            Hyperliquid fees have exceeded $700 million since inception</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cumulative
                                            cryptocurrency perpetuals trading volume on Hyperliquid has exceeded $3 trillion since inception</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 0.25in; padding-left: 0.25in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Digital Assets Business Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the Company first
pivoted to its Hyperliquid DeFi strategy, we have continued to emphasize that our business is &ldquo;more than just HYPE&rdquo;. The
accumulation of HYPE is the first step in a broader DeFi monetization roadmap that continues to accelerate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">As part of its broader
onchain engagement strategy, the Company announced a co-branded Hyperliquid validator, referred to as &ldquo;Kinetiq x
Hyperion&rdquo;, with Kinetiq Research Pte. Ltd. (&ldquo;Kinetiq Group&rdquo;), which is a liquid staking protocol built natively
for the Hyperliquid ecosystem. Validator operations are further supported by infrastructure provided by Pier Two Pty Ltd
(&ldquo;Pier Two&rdquo;), an institutional staking services provider. Under our Joint Validator Operators&rsquo; Agreement with
Kinetiq Group and Pier Two, staking commissions and other validator-level rewards are allocated among Hyperion (50%), Kinetiq Group
(25%) and Pier Two (25%), with specific overrides for referred delegations. By running our own validator, the Company can directly
access HYPE staking yield in addition to supporting Hyperliquid&rsquo;s network stability and security. With the rapid growth of our
Kinetiq x Hyperion validator, which has over 13 million in delegated HYPE as of October 31, 2025, we play a meaningful role in
stewarding the future growth of the Hyperliquid ecosystem, given that HYPE holdings are required to participate in ecosystem
governance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.5in; margin: 0pt 0">The Company currently stakes
a majority of its HYPE tokens as part of its broader participation in the Hyperliquid ecosystem. Under its operational policy, the Company
utilizes staked HYPE to serve as the foundation for certain revenue-generating strategies, including the Company&rsquo;s proprietary
HYPE Asset Use Service (HAUS) product. These strategies are made possible through technical infrastructure unique to Hyperliquid, which
can deploy staked HYPE across various utilities in the Hyperliquid ecosystem, such as significantly reduced trading fees and the ability
to support new non-crypto markets on the Hyperliquid platform, both of which the Company has productized and offered to clients as services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">More
recently, the Hyperliquid network implemented the HIP-3 (Hyperliquid Improvement Proposal 3) upgrade, which enables any user with 500,000
HYPE staked at a deployer address to launch a custom on-chain perpetual futures market for non-crypto assets such as equities, commodities
and indices. These network upgrades expand both Hyperliquid&rsquo;s product suite and its potential user base, further establishing it
as a premier on-chain destination for financial activity. To support HIP-3, the Company provided Felix, one of the earliest HyperEVM
protocols, with the HYPE required to launch a perpetual futures market and will earn a share of the fees earned from trading activity.
This perpetual futures market is operated and maintained by Felix and is accessible only to non-U.S. persons. Because the perpetual futures
market is not currently subject to regulation by the U.S. Commodity Futures Trading Commission and perpetual futures are not permitted
for unrestricted trading in the United States, this perpetual futures market is operated outside the United States and is not made available
to or marketed to U.S. persons. </FONT>Beyond engaging with Hyperliquid&rsquo;s flagship exchange product, users can also deploy HYPE
into the HyperEVM for various strategies such as lending and liquidity provisioning. The Company is the first public company on HyperEVM,
staking a significant portion of its native HYPE into Kinetiq Group&rsquo;s uniquely designed iHYPE (institutional HYPE) product. This
enabled the Company to earn staking yield on its HYPE while also gaining access to a unique liquid receipt token, HiHYPE (Hyperion iHYPE),
which is used for various on-chain and off-chain strategies. The Company has also earned kPoints, a participation-based incentive that
qualified the Company to receive a portion of the airdrop of Kinetiq Group&rsquo;s KNTQ token. This reflects yet another DeFi strategy
that translates into additional yield from and ownership of key products built on Hyperliquid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Anchorage Digital Bank
National Association (&ldquo;Anchorage Digital&rdquo;), which recently rolled out full support asset custody on HyperEVM, provides
custody and trade execution services for HYPE. Anchorage Digital is the only federally chartered cryptocurrency bank in the United
States, serves as a custodian for digital assets, and is licensed and regulated by the Office of the Comptroller of the Currency.
Anchorage Digital has institutional-grade security required by institutional investors and employs HSM (Hardware Security Module)
for a unique security model for secure digital assets. We believe that Anchorage Digital&rsquo;s public support for Hyperliquid by
prioritizing development of infrastructure uniquely for Hyperliquid is a testament to the future prospect of the Hyperliquid
ecosystem. Currently, Anchorage Digital provides only custodial services to the Company and does not use a sub-custodian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Because Anchorage Digital does not currently support the HyperCore
infrastructure required for the Company&rsquo;s strategy to stake HYPE and operate on-chain, HYPE used for those purposes must be held
in self-custodied wallets. The Company holds its HYPE in self-custodied cold wallet addresses using infrastructure provided by regulated
custodians, including Porto by Anchorage Digital, and hardware wallet providers such as Ledger. These arrangements provide the Company
flexibility to reallocate HYPE among its wallet addresses, and holdings may be concentrated with a single infrastructure provider from
time to time. To support security of its self-custodied cold wallets, the Company utilizes the Porto security infrastructure as well as
additional protections such as a HyperCore-native multi-signature configuration that requires multiple Company-owned addresses as additional
signers. The Company will periodically evaluate additional custody infrastructure providers to support operational flexibility as its
HYPE strategy evolves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition to security infrastructure, Anchorage Digital, through which the Company maintains an account,
provides certain enterprise-level insurance policies that apply to assets held in its custodial accounts, including crime insurance with
a $100 million limit, general liability coverage with a $4 million limit, cyber and technology errors and omissions coverage with a $1
million limit, and other standard liability coverages. Digital assets that the Company self-custodies are not covered by these insurance
policies. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">By prudently building and deploying a treasury
of HYPE, the Company believes that it can rapidly accelerate the growth of the Hyperliquid ecosystem and further its adoption, potentially
creating a powerful flywheel effect that may drive platform usage, increase protocol value and strengthen the long-term position of both
the Hyperliquid ecosystem and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25pt; text-indent: -0.7pt"><U>Overview of the HYPE Token
Lifecycle</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25pt; text-indent: -0.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.7pt"><B>HYPE Creation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">The
circulating supply of HYPE is approximately 337 million tokens as of October 31, 2025. The first token generation event occurred on November
29, 2024, with approximately 310 million tokens created and circulated. Approximately 389 million HYPE tokens are reserved for future
community rewards and emissions. Approximately 238 million HYPE tokens are reported to be vesting to core contributors of the Hyperliquid
blockchain beginning November 29, 2025 and continuing over a multi-year vesting schedule. The total maximum supply of HYPE that can ever
be created is fixed at 1 billion tokens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">HYPE
Acquisition and Sale Process</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">Our management team continually
reviews the Company's short-term obligations and the excess cash available for dedication to our HYPE treasury strategy. When we determine
that the Company has excess capital available to deploy, we work with institutional digital asset trading venues and counterparties to
acquire HYPE from institutional sellers<B>.</B> Our HYPE acquisition process is designed to maximize the quantity of HYPE that we acquire
with the capital that we have, while minimizing market impact and execution risk. While we have never resold any of our HYPE tokens as
of October 31, 2025, we would anticipate only selling our HYPE tokens to institutional counterparties and trading venues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">HYPE
Token Custody</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">We hold our HYPE in self-custodied
cold wallet addresses, using infrastructure provided by regulated custodians, including Porto by Anchorage Digital Bank, as well as hardware
wallet providers such as Ledger. In light of the significant amount of HYPE that we hold, we continually engage with additional custody
infrastructure providers (such as BitGo and Fireblocks) to achieve a greater degree of diversification in the custody of our HYPE, as
the extent of potential risk of loss depends, in part, on the degree of diversification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25pt; text-indent: -0.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>HYPE
Native Staking &amp; Validating</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25pt; text-indent: -0.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">On the Hyperliquid Network, staking
rewards are determined by the protocol and are distributed to validators and their associated stakers based on the proportion of their
stake relative to the total active HYPE staked in the network. The rewards come from Hyperliquid's future emissions reserve. The staking
reward rate formula is inspired by Ethereum's model, where the reward rate is inversely proportional to the square root of total HYPE
staked. As of October 31, 2025, the annual reward rate is approximately 2.2% per year (net rate after validator commission, which varies
among individual validators). Rewards are accrued continuously (every minute) and are automatically distributed and compounded daily
with automatic redelegation to the staked validator. This means that Hyperion DeFi's staking balance grows automatically, without requiring
manual intervention or claiming transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">Hyperion DeFi operates a dedicated
validator node on Hyperliquid in partnership with Kinetiq and Pier Two, under its Kinetiq x Hyperion Joint Validator Agreement. Through
the Kinetiq x Hyperion validator, Hyperion DeFi participates directly in Hyperliquid's consensus and block production. The validator
receives validator rewards proportional to its total delegated stake, earns transaction fees from blocks it proposes, generates validator
commission income from HYPE stakers who delegate to it, and contributes to Hyperliquid Network decentralization by operating a professional
validator node.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">As noted above, the Company currently stakes a majority of its HYPE tokens. Staking provides revenues to the Company in
the form of staking yields, but creates liquidity risks given that staked tokens are not sellable until a seven-day un-staking queue
is completed. The Company anticipates operating with enough cash and cash equivalents to cover its expenses and any debt payments.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25pt; text-indent: -0.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25pt; text-indent: -0.7pt">HYPE Liquid Staking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">Liquid staking allows Hyperion
DeFi to earn staking rewards while maintaining liquidity and accessing additional yield opportunities. Through liquid staking, we deposit
HYPE to a non-custodial liquid staking protocol and receive liquid staking tokens in return that represent our staked position and accrued
rewards. These liquid staking tokens may be used throughout the HyperEVM ecosystem in decentralized finance applications, while the underlying
HYPE remains staked and earning consensus-layer rewards. Hyperion DeFi participates in liquid staking through Kinetiq, a non-custodial
liquid staking protocol built on Hyperliquid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">When Hyperion DeFi deposits HYPE to Kinetiq for staking, we receive liquid staking tokens
such as &ldquo;HiHYPE&rdquo; or &ldquo;kHYPE&rdquo;, which represent a proportional claim on the underlying staked HYPE and accrued staking
rewards, remains liquid and tradeable on HyperEVM's decentralized exchanges, automatically accrues staking rewards with the token balance
increasing daily, can be redeemed for HYPE at any time (subject to liquidity and redemption queue conditions), and can be held, traded,
or deployed in DeFi strategies without unstaking the underlying HYPE. The Kinetiq protocol operates non-custodially, meaning Kinetiq
does not take possession or control of user HYPE; instead, users retain cryptographic control and can verify that their HYPE is staked
to designated validators on HyperCore at all times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25pt; text-indent: -0.7pt">HYPE Asset Use Service (HAUS)
and Protocol Partnerships</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">Beyond core staking, Hyperion
DeFi supplies HYPE inventory to third-party DeFi protocols in structured arrangements known as HYPE Asset Use Services (HAUS). For example,
Hyperion DeFi has entered into arrangements with Felix, a HIP-3-powered perpetual futures protocol, to supply HYPE inventory to support
custom markets and derivative trading strategies. Under HAUS arrangements, the Company&rsquo;s partners use the HYPE inventory to enable
unique on-chain utility, and the Company receives compensation in the form of fees on transaction volume, revenue share from protocol
earnings, additional HYPE or other tokens as incentive payments, and potentially equity or governance tokens in the protocol. These arrangements
are contractually documented and operate within specified risk parameters managed by Hyperion DeFi's treasury and risk policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.7pt"><B>Hyperliquid Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">Governance of the Hyperliquid
protocol is conducted through a decentralized, token-based voting system. Holders of HYPE tokens can propose and vote on protocol upgrades,
parameter changes, and treasury allocations. Governance decisions are executed on-chain via smart contracts, ensuring transparency and
immutability. The governance framework is designed to align incentives among stakeholders and promote long-term protocol sustainability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0.5pt; text-indent: -0.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Optejet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hyperion DeFi is also developing the proprietary
Optejet User Filled Device (the &ldquo;Optejet UFD&rdquo;) that is designed to work with a variety of topical ophthalmic liquids, including
artificial tears and lens rewetting products. The Optejet UFD is especially useful in chronic front-of-the-eye diseases due to its ease
of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may
result in higher treatment compliance and better outcomes for patients and providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ergonomic and functional design of the
Optejet UFD allows for horizontal drug delivery and eliminates the need to tilt the head back or the manual dexterity to squeeze a bottle
to administer medications. Drug is delivered in a microscopic array of droplets that is comfortable and matches the amount of fluid that
the front of the eye can hold. The precise delivery of a low-volume columnar spray by the Optejet UFD helps ensure instillation success
while minimizing contamination risk with a non-protruding nozzle and self-closing shutter. In clinical trials, the Optejet UFD has demonstrated
that its targeted delivery achieves a high rate of successful administration, with 98% of sprays being accurately delivered upon first
attempt compared to the established rate reported with traditional eye drops of approximately 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A more physiologically appropriate volume of
medication in the range of seven to ten microliters is delivered by the Optejet UFD, which is approximately one-fifth of the 35 to 50
microliter dose typically delivered in a single eye drop. Lower volume of medication exposes the ocular surface to less active ingredients
and preservatives, potentially reducing ocular stress and surface damage and improving tolerability. The lower volume also minimizes
the potential for drug to enter systemic circulation, with the goal of avoiding some common side effects that are related to overdosing
of the eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We anticipate registering the second generation
of the Optejet UFD as a liquid drug delivery device, based on our experience with MydCombi&reg;. MydCombi was the only Food and Drug Administration-approved
fixed combination of the two leading mydriatic agents, tropicamide and phenylephrine, in the United States delivered with technology that
is nearly identical to the first generation of the Optejet UFD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Private Placement and Capital Raising</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 20, 2025, we received approximately
$50 million in gross proceeds, or $45 million after deducting placement agent fees and offering expenses, in connection with the closing
of a private placement (the &ldquo;Private Placement&rdquo;). Pursuant to the Securities Purchase Agreement, in the Private Placement,
the Purchasers purchased an aggregate of 5,128,205 shares of Series A Preferred Stock (convertible into up to 15,384,615 shares of Common
Stock) and Purchaser Warrants to purchase up to 30,769,230 shares of Common Stock at an exercise price of $3.25 per share. The Company
used all of the proceeds from the Private Placement to make purchases of and build a reserve of HYPE. As part of its new cryptocurrency
treasury strategy, the Company has begun implementing a HYPE staking program. Following the completion of the Private Placement, the
Company has purchased an additional $10.5 million of HYPE, for a total of $55.5 million used for HYPE purchases to date. Going forward,
subject to market conditions, the Company intends to raise additional proceeds through equity financings to purchase additional HYPE
for our treasury, although we cannot currently estimate how much we will raise or when such purchases will occur. The Company intends
to use a portion of the proceeds from the exercise of the Warrants, if any, which could be up to a maximum of approximately $100 million,
to purchase additional HYPE. The Company&rsquo;s other plans to raise capital include the use of our at-the-market offering sales agreement
with Cantor Fitzgerald &amp; Co. and Chardan Capital Markets, LLC (&ldquo;Chardan&rdquo;) and other future equity offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 0.25in; padding-left: 0.25in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Chardan acted as placement agent to the Company
in connection with the Private Placement. Pursuant to the Engagement Letter, as compensation for its services, the Company issued to
Chardan 307,692 shares of Series A Preferred Stock (convertible into up to 923,076 shares of Common Stock) and Placement Agent Warrants
to purchase up to 1,846,153 shares of Common Stock at an exercise price of $3.25 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fourth Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On June&nbsp;17, 2025,
the Company and the Lenders entered into the Fourth Amendment. The Fourth Amendment, among other things, extends the maturity date of
the loans under the Loan and Security Agreement to July&nbsp;1, 2028; provides for an interest-only period from July&nbsp;1, 2025 until
January&nbsp;31, 2027; reduces the interest rate on the loans from 12.0% to 8.0%, payable half in cash and half in kind; eliminates the
option of the Lenders to convert an aggregate amount of up to $10.0 million of the loans outstanding into shares of Common Stock; and
provides the Company with the option to prepay debt owed under the Loan and Security Agreement in part, subject to certain limitations.
In connection with the Fourth Amendment, the Company issued to the Lenders Warrants to purchase an aggregate of 350,000 shares of Common
Stock at an exercise price of $4.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were organized as a corporation under the laws
of the State of Florida on March&nbsp;12, 2014 under the name &ldquo;PGP Holdings V,&nbsp;Inc.&rdquo; On May&nbsp;5, 2014, we changed
our name to Eyenovia,&nbsp;Inc. On October&nbsp;6, 2014, we reincorporated in the State of Delaware by merging into Eyenovia,&nbsp;Inc.,
a Delaware corporation. On July&nbsp;1, 2025, we changed our name to Hyperion DeFi,&nbsp;Inc. Our principal executive office is located
at 23461 S. Pointe Drive, Suite&nbsp;390, Laguna Hills, CA 92653, and our telephone number is (833) 393-6684. We maintain a website at
www.hyperiondefi.com, to which we regularly post copies of our press releases as well as additional information about us. The information
contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a &ldquo;smaller reporting company&rdquo;
as defined under the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies
until the last day of the fiscal year in which (i)&nbsp;the market value of our Common Stock held by non-affiliates exceeds $250 million
as of the end of that year&rsquo;s second fiscal quarter and our annual revenue exceeds $100 million during such completed fiscal year,
or (ii)&nbsp;the market value of our Common Stock held by non-affiliates exceeds $700 million, regardless of our annual revenue, as of
the end of that year&rsquo;s second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 0.25in; padding-left: 0.25in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock offered by the Selling Securityholders</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 50,770,667 shares of Common Stock, which includes up to </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">16,307,691 shares of Common Stock issuable upon the conversion of the 5,435,897 outstanding shares of Series&nbsp;A Preferred Stock, up to 1,497,593 shares of Common Stock issuable as in-kind dividends on such Series&nbsp;A Preferred Stock and up to 32,965,383 shares of Common Stock issuable upon the exercise of the Warrants.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms of the offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Securityholders may, from time to time, sell, at prevailing market prices, privately negotiated prices or such other prices as the Selling Securityholders may determine, any or all of their securities covered hereby. See &ldquo;Plan of Distribution.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock to be outstanding after this offering,
    assuming cash exercise of the Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>58,943,326 shares, assuming the conversion of the outstanding shares of Series&nbsp;A Preferred Stock, issuance of 1,497,593
    shares of Common Stock as in-kind dividends on the Series&nbsp;A Preferred Stock and exercise of the Warrants in full.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of Proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>We will not receive any of the proceeds from the sale of our securities by the Selling Securityholders. See &ldquo;Use of
    Proceeds.&rdquo; If the Warrants were to be exercised in full for cash, as to which no assurance can be given, we would receive an
    aggregate of approximately $107.4 million in proceeds. Any such proceeds would be used for working capital and general corporate
    purposes (including to build the Company&rsquo;s reserve of the HYPE token).</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities involves a high degree
of risk. See &ldquo;Risk Factors&rdquo; on page&nbsp;9 of this prospectus to read about factors that you should consider carefully before
buying our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Trading Market and Ticker Symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock is listed on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The Nasdaq Capital Market under the symbol &ldquo;HYPD.&rdquo; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The number of shares of common stock outstanding
immediately after this offering is based on 8,172,659 shares of Common Stock outstanding as of December 1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This number excludes:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,577 shares of our Common Stock
    underlying outstanding options to purchase Common Stock under our 2014 Equity Incentive Plan, as amended (the &ldquo;2014 Plan&rdquo;)
    and our Amended and Restated 2018 Omnibus Stock Incentive Plan (the &ldquo;2018 Plan&rdquo;) with a weighted average exercise price
    of $86.32 per share as of December 1, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,578,151 shares of our Common Stock issuable in
    connection with restricted stock units under the 2014 Plan and the 2018 Plan as of December 1, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,769,052 shares of our Common Stock reserved for
    future issuance under the 2014 Plan and the 2018 Plan as of December 1, 2025; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase 855,401 shares of our Common
    Stock, with a weighted average exercise price of $14.24 per share as of December 1, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000 shares of our Common Stock issuable in connection
    with restricted stock units to be granted as an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4); and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,954 shares of our Common Stock issuable as compensation
    in connection with vendor contracts.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="a_004"></A><B>RISK FACTO</B></FONT><B>RS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investing in our securities involves a high degree
of risk. You should consider carefully the risks and uncertainties, as well as other information, in this prospectus, including the risks
described under &ldquo;Risk Factors&rdquo; in our most recent Annual Report on Form&nbsp;10-K and subsequent Quarterly Reports on Form&nbsp;10-Q,
and all other information contained or incorporated by reference into this prospectus. The risks set forth in this prospectus and incorporated
herein by reference are those which we believe are the material risks that we face. These risks are not the only ones facing us and there
may be additional matters that we are unaware of or that we currently consider immaterial. The occurrence of any of such risks may materially
and adversely affect our business, financial condition, results of operations and future prospects. In such an event, the market price
of our Common Stock could decline, and you could lose part or all of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may need to raise&nbsp;additional capital in the future, which
may not be available on reasonable terms, or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We require significant capital resources in
order to continue to operate our business. As of September 30, 2025, we had cash and cash equivalents of $8.2 million and an accumulated
deficit of approximately $200.9 million. Also as of September 30, 2025, we owed $8.3 million in principal and accrued interest under
the Loan and Security Agreement. We expect to continue to incur cash outflows from operations for the near future. Implementation of
our plans will depend on many factors, including our ability to successfully commercialize our products and services, competing technological
and market developments, and the need to enter into collaborations with other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also, it is very difficult to project our current
monthly cash burn rate, and we may expend our resources sooner than we anticipate. Although we have the ability to liquidate HYPE tokens
to fund our operations, any required additional capital may not be available on reasonable terms, if at all, due to a variety of factors,
including volatile conditions in the economy and capital markets, due to inflation, questions about bank stability and other factors.
If we are unsuccessful in our operations to secure additional financing, or if any such incremental financing is not sufficient to fund
our operations, we may be required to take additional measures to reduce costs in order to conserve our cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may not be able to obtain financing on favorable
terms, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our then current stockholders
will be reduced, and the holders of the new equity securities may have rights superior to those of our then existing securityholders,
which could adversely affect the market price of our Common Stock and the voting power of shares of our Common Stock. If we raise additional
funds by issuing debt securities or preferred stock, the holders of such securities may have rights that are senior to those of our then
existing securityholders, and the terms of those securities could impose restrictions on operations and create a significant interest
expense for us, which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Delisting of our Common Stock from Nasdaq could prevent us from
maintaining an active, liquid and orderly trading market for our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ability to publicly or privately sell equity
securities and the liquidity of our Common Stock would be adversely affected if we are delisted from The Nasdaq Capital Market or if
we are unable to transfer our listing to another stock market. On September&nbsp;18, 2024, we were notified by The Nasdaq Stock Market
LLC, or Nasdaq, that we were in breach of Listing Rule&nbsp;5550(a)(2) (the &ldquo;Minimum Bid Price Rule&rdquo;), for continued listing
on the Nasdaq Capital Market because the minimum bid price of our listed securities for 30 consecutive business days had been less than
$1 per share. On December&nbsp;12, 2024, we received a letter from Nasdaq notifying us that, because the closing bid price for our Common
Stock was below $0.10 per share for 10 consecutive trading days, we were in breach of Listing Rule&nbsp;5810(c)(3)(A)(iii). On January&nbsp;31,
2025, we executed an 80-for-1 reverse stock split, following which we were notified by Nasdaq that we had regained compliance with the
Minimum Bid Price Rule. Nasdaq Listing Rule&nbsp;5810(c)(3)(A)(iv)&nbsp;states that any listed company that fails to meet the Minimum
Bid Price Rule&nbsp;and has effected a reverse stock split over the prior one-year period, or has effected one or more reverse stock
splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, will not be eligible for an automatic 180-day
grace compliance period and the Nasdaq Listing Qualifications Department is obligated to immediately issue a delisting determination.
Therefore, if we were to fall out of compliance with the Minimum Bid Price requirement prior to January&nbsp;31, 2026, we would not be
able to effect a reverse stock split and would immediately be issued a delisting determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&nbsp;29, 2025, we received a notice
from the staff of the Nasdaq stating that the Company&rsquo;s stockholders&rsquo; equity as reported in the Company&rsquo;s Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31, 2024 was below the Minimum Equity Requirement. On September 2, 2025, we received
a notice from the staff indicating that the Company has regained compliance with the Minimum Equity Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our Common Stock is delisted by Nasdaq, it could
lead to a number of negative implications, including an adverse effect on the price of our Common Stock, deterring broker-dealers from
making a market in or otherwise seeking or generating interest in our Common Stock, increased volatility in our Common Stock, reduced
liquidity in our Common Stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing.
Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our
business and future prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our Common Stock is delisted by Nasdaq, the
price of our Common Stock may decline, and although our Common Stock may be eligible to trade on the OTC Bulletin Board, another over-the-counter
quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their Common Stock or obtain accurate quotations
as to the market value of our Common Stock. If our Common Stock is delisted from Nasdaq, trading in our securities may be subject to the
SEC&rsquo;s &ldquo;penny stock&rdquo; rules. These &ldquo;penny stock&rdquo; rules&nbsp;will require brokers trading in our Common Stock
to adhere to more stringent rules&nbsp;and possibly result in a reduced level of trading activity in the secondary trading market for
our Common Stock. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending
transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market
price for our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, if our Common Stock is delisted, we would
incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit
the market liquidity of our Common Stock and the ability of our stockholders to sell our Common Stock in the secondary market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>HYPE is a highly volatile asset, and fluctuations in the price
of HYPE may influence our financial results and the market price of our listed securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our financial results and the market price of our
listed securities would be adversely affected, and our business and financial condition would be negatively impacted, if the price of
HYPE decreased substantially, including as a result of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased user and investor confidence in HYPE, including due to the various factors described herein;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investment and trading activities such as (i)&nbsp;trading activities of highly active retail and institutional users, speculators and investors or (ii)&nbsp;actual or expected significant dispositions of HYPE by large holders, including the expected liquidation of digital assets seized by governments or associated with entities that have filed for bankruptcy protection, or associated with tokens vested by the Hyperliquid core team;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative publicity, media or social media coverage, or sentiment due to events in or relating to, or perception of, HYPE, Hyperliquid or the broader digital assets industry;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in consumer preferences and the perceived value or prospects of HYPE or the utility of Hyperliquid;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition from other decentralized exchanges or digital assets that exhibit comparable or better speed, security, scalability or energy efficiency, that feature other more favored characteristics, that are backed by governments, including the U.S. government, or reserves of fiat currencies, or that represent ownership or security interests in physical assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a decrease in the price of other digital assets, to the extent the decrease in the price of such other digital assets may cause a decrease in the price of HYPE or adversely affect investor confidence in digital assets generally;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments relating to the Hyperliquid blockchain, including (i)&nbsp;changes to the Hyperliquid blockchain that impact its security, speed, scalability, usability or value, such as changes to the cryptographic security protocol underpinning the Hyperliquid blockchain, changes to the maximum number of HYPE outstanding, changes to the mutability of transactions, changes relating to the size of blockchain blocks, and similar changes; (ii)&nbsp;failures to make upgrades to the Hyperliquid blockchain and the Hyperliquid interface to adapt to security, technological, legal or other challenges; and (iii)&nbsp;changes to the Hyperliquid blockchain that introduce software bugs, security risks or other elements that adversely affect HYPE;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions, failures, unavailability, or interruptions in services of trading venues for HYPE;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the filing for bankruptcy protection by, liquidation of, or market concerns about the financial viability of digital asset custodians, trading venues, lending platforms, investment funds, or other digital asset industry participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory, legislative, enforcement and judicial actions that adversely affect access to, functionality of or performance of Hyperliquid and its associated products such as cryptocurrency perpetual futures, the price, ownership, transferability, trading volumes, legality or public perception of, HYPE or other L1 blockchains, or that adversely affect the operations of or otherwise prevent digital asset custodians, trading venues, lending platforms or other digital assets industry participants from accessing the Hyperliquid decentralized exchange and its associated products or operating in a manner that allows them to continue to deliver services to the digital assets industry;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transaction congestion and fees associated with processing transactions on the Hyperliquid network;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">macroeconomic changes, such as changes in the level of interest rates and inflation, fiscal and monetary policies of governments, trade restrictions and fiat currency devaluations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments in mathematics or technology, including in digital computing, algebraic geometry and quantum computing, that could result in the cryptography used by the Hyperliquid blockchain becoming insecure or ineffective; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in national and international economic and political conditions, including, without limitation, federal government policies, trade tariffs and trade disputes, and the adverse impacts attributable to global conflicts, including those between Russia and Ukraine and in the Middle East.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The price of our listed securities has been
and is likely to continue to be volatile, and with the adoption of our new cryptocurrency treasury strategy, we expect to see additional
volatility in our stock price. In addition, if investors view the value of our listed securities as dependent upon or linked to the value
or change in the value of our HYPE holdings, the price of HYPE may significantly influence the market price of our listed securities.
The price of HYPE has historically been, and is likely to continue to be, volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>HYPE is subject to extreme price volatility,
and any sustained decline in the market price of HYPE could lead to substantial losses on our digital asset holdings and could adversely
affect the market price of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The price of HYPE has exhibited sudden and
significant fluctuations due to shifts in market sentiment, speculative trading, macroeconomic trends, technology-related disruptions,
and regulatory announcements. Because digital asset trading markets are relatively new, largely unregulated, and, at times, subject to
limited liquidity, HYPE may experience larger or more frequent price swings than traditional asset classes. A rapid decrease in the price
of HYPE -whether the result of negative perception, a lack of stability on the digital asset trading platforms on which HYPE trades,
market manipulation of cryptocurrency trading platforms by customers, a cyber-security incident, regulatory action, or other factors-could
materially reduce the value of any HYPE we hold, force us to recognize impairment charges, and depress the market price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, large portions of HYPE, potentially 238 million HYPE
tokens or more, have been reported to be held by the Hyperliquid core contributors. As a result, trading activity by these parties could
have a material impact on the price and trading volume of HYPE. Further, to our knowledge, the core contributors and other large holders
of HYPE began to &ldquo;unlock&rdquo; their tokens on November 29, 2025, meaning that they became able to sell some of their HYPE starting
on such date and at periodic unlock dates over a multi-year vesting schedule. The large influx of HYPE increases the circulating supply,
which can lead to a price drop if demand does not increase proportionally to absorb the new tokens. If all HYPE tokens that were unlocked
on that day and are unlocked on future unlock dates are immediately sold, this could have significant impacts on the price of HYPE on
or around such unlock dates and depress the price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to raise sufficient additional capital on
acceptable terms, we may be unable to expand or maintain our HYPE reserve, which could adversely affect our liquidity, financial condition
and growth prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We completed the Private Placement on June
20, 2025 pursuant to the securities Purchase Agreement, the net proceeds of which have been used for our HYPE treasury strategy. To the
extent holders exercise the Warrants, we may acquire additional HYPE at market prices, which could magnify our exposure to HYPE price
volatility. If we are unable to raise sufficient additional capital through warrant exercises, our at-the-market facility or other equity
financings on acceptable terms, we may be unable to expand or maintain our HYPE reserve, which could adversely affect our liquidity,
financial condition and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>We face risks relating to the custody of
our HYPE, including the loss or destruction of private keys required to access our HYPE and cyberattacks or other data loss relating
to our HYPE, including smart contract related losses and vulnerabilities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hold our HYPE in self-custodied wallet addresses,
using infrastructure provided by regulated custodians, including Anchorage Digital Bank, as well as hardware wallet providers. Our custodial
services contracts do not restrict our ability to reallocate our HYPE among our wallet addresses, and our HYPE holdings may be concentrated
with a single custodian from time to time. In light of the significant amount of HYPE that we hold, we expect to continually seek to
engage additional custody infrastructure providers to achieve a greater degree of diversification in the custody of our HYPE as the extent
of potential risk of loss is dependent, in part, on the degree of diversification. However, multiple custody infrastructure providers
may utilize similar wallet infrastructure, cloud service providers or software systems, which could increase systemic technology risk.
While we will conduct due diligence on our custody infrastructure providers and any smart contract platforms we may use, there can be
no assurance that such diligence will uncover all risks, including operational deficiencies, hidden vulnerabilities or legal noncompliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The digital assets held by us are not insured.
The market for such insurance is in the early stages. Further, banking institutions will not accept our digital assets and they are therefore
not insured by the Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;) or the Securities Investor Protection Corporation (&ldquo;SIPC&rdquo;).
Therefore, a loss may be suffered with respect to our digital assets which is not covered by insurance and we may not be able to recover
any of our carried value in these digital assets if they are lost or stolen or suffer significant and sustained reduction in conversion
spot price. If we are not otherwise able to recover damages from a malicious actor in connection with these losses, our business and
results of operations may suffer, which may have a material negative impact on our share price. The limited rights of legal recourse
available to us and our lack of insurance protection for risk of loss of our digital assets exposes us and our shareholders to the risk
of loss of our digital assets for which no person may ultimately be held liable and we may not be able to recover our losses. Any uninsured
losses may have an adverse effect on our results of operations and/or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent that we obtain insurance to cover
losses of our HYPE holdings in the future, such insurance may cover none or only a small fraction of the value of the entirety of our
HYPE holdings. Any loss associated with any insolvency proceedings is unlikely to be covered by any insurance coverage we may obtain
in the future related to our HYPE. The legal framework governing digital asset ownership and rights in custodial or insolvency contexts
remains uncertain and continues to evolve, which could result in unexpected losses, protracted recovery processes or adverse treatment
in insolvency proceedings. HYPE is controllable only by the possessor of both the unique public key and private key(s) relating to the
local or online digital wallet in which the HYPE is held. While the L1 blockchain ledger requires a public key relating to a digital
wallet to be published when used in a transaction, private keys must be safeguarded and kept private in order to prevent a third party
from accessing the HYPE held in such wallet. To the extent the private key(s) for a digital wallet are lost, destroyed, or otherwise
compromised and no backup of the private key(s) is accessible, neither we nor our custody infrastructure providers will be able to access
the HYPE held in the related digital wallet. Furthermore, we cannot provide assurance that our digital wallets, nor the digital wallets
of our custody infrastructure providers, will not be compromised as a result of a cyberattack. The HYPE and blockchain ledger, as well
as other digital assets and blockchain technologies, have been, and may in the future be, subject to security breaches, cyberattacks
or other malicious activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of our treasury management strategy,
we may engage in staking, restaking, or other permitted activities that involve the use of &ldquo;smart contracts&rdquo; or decentralized
applications. The use of smart contracts or decentralized applications entails certain risks including risks stemming from the existence
of an &ldquo;admin key&rdquo; or coding flaws that could be exploited, potentially allowing a bad actor to issue or otherwise compromise
the smart contract or decentralized application, potentially leading to a loss of our HYPE. Like all software code, smart contracts are
exposed to risk that the code contains a bug or other security vulnerability, which can lead to loss of assets that are held on or transacted
through the contract or decentralized application. Smart contracts and decentralized applications may contain bugs, security vulnerabilities
or poorly designed permission structures that could result in the irreversible loss of HYPE or other digital assets. Exploits, including
those stemming from admin key misuse, admin key compromise, or protocol flaws, have occurred in the past and may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and the documents we have filed
with the SEC that are incorporated by reference herein contain &ldquo;forward-looking statements&rdquo; within the meaning of Section&nbsp;27A
of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section&nbsp;21E of the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;). These statements relate to future events or to our future operating or financial performance
and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to
be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
Forward-looking statements may include, but are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our estimates regarding expenses, future revenue, timing of any future revenue,
capital requirements and needs for additional financing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            viability of, and risks associated with, our cryptocurrency treasury strategy;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to make payments on our debt;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our expectations related to the use of proceeds from our financings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our intellectual property position;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to attract and retain key personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of government laws and regulations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our competitive position;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">developments relating to our competitors and our industry;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain and establish collaborations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">general or regional economic conditions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in U.S. GAAP; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in the legal, regulatory and legislative environments in the markets
in which we operate, and the impact of these changes on our ability to obtain regulatory approval for our products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In some cases, you can identify forward-looking
statements by terms such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
 &ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar
expressions or variations intended to identify forward- looking statements. These statements reflect our current views with respect to
future events, are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. More information on factors that could cause actual results to differ materially from those
anticipated is included from time to time in our reports filed with the SEC, including, but not limited to, those described in the section
titled &ldquo;Risk Factors&rdquo; in our Annual Report on Form&nbsp;10-K for our most recent fiscal year, as updated by our subsequent
filings under the Exchange Act, which are incorporated herein by reference, and as may be updated or superseded by the risks and uncertainties
described under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus.
Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should read this prospectus and the documents
we have filed with the SEC that are incorporated by reference herein completely and with the understanding that our actual future results
may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these
cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless required by law, we undertake no obligation
to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not
assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not receive any of the proceeds from
the sale of Common Stock by the Selling Securityholders named in this prospectus. If the Warrants were to be exercised in full for cash,
as to which no assurance can be given, we would receive an aggregate of approximately $107.4 million in proceeds. Any such proceeds would
be used for working capital and general corporate purposes (including to build the Company&rsquo;s reserve of the HYPE token).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>SELLING SECURITYHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus relates to the offer and sale
from time to time by the Selling Securityholders listed below of (i)&nbsp;up to 15,384,615 shares of Common Stock issuable upon the conversion
of 5,128,205 shares of Series&nbsp;A Preferred Stock that were issued pursuant to the Securities Purchase Agreement; (ii)&nbsp;up to 30,769,230
shares of Common Stock issuable upon the exercise of the Purchaser Warrants; (iii)&nbsp;up to 923,076 shares of Common Stock issuable
upon the conversion of 307,692 shares of Series&nbsp;A Preferred Stock that were issued pursuant to the Engagement Letter; (iv)&nbsp;up
to 1,846,153 shares of Common Stock issuable upon the exercise of the Placement Agent Warrants; (v)&nbsp;up to 1,497,593 shares of Common
Stock issuable as in-kind dividends on the Series&nbsp;A Preferred Stock; and (vi)&nbsp;up to 350,000 shares of Common Stock issuable
upon the exercise of the Lender Warrants. We are registering these securities for sale by the Selling Securityholders to satisfy certain
registration rights that we have granted to the Selling Securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Securityholders may from time to time
offer and sell any or all of the Common Stock set forth below pursuant to this prospectus. As used in this prospectus, the term &ldquo;Selling
Securityholders&rdquo; includes the persons listed in the table below, together with any additional selling securityholders listed in
a subsequent amendment to this prospectus, and their pledgees, donees, transferees, assignees, successors, designees and others who later
come to hold any of the Selling Securityholders&rsquo; interests in the Common Stock, other than through a public sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as set forth below, the following table
sets forth certain information as of December 1, 2025 regarding the beneficial ownership of the Common Stock being offered by the Selling
Securityholders. The applicable percentage ownership of Common Stock is based on 8,172,659 shares of Common Stock outstanding as of December
1, 2025. Information with respect to Common Stock owned beneficially after the offering assumes the sale of all of the Common Stock registered
hereby and assumes no further acquisitions or dispositions of securities by the Selling Securityholders. The Selling Securityholders
may offer and sell some, all or none of their Common Stock pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Beneficial ownership is determined in accordance
with the rules&nbsp;and regulations of the SEC. A person is a &ldquo;beneficial owner&rdquo; of a security if that person has or shares
 &ldquo;voting power,&rdquo; which includes the power to vote or to direct the voting of the security, or &ldquo;investment power,&rdquo;
which includes the power to dispose of or to direct the disposition of the security, or has the right to acquire such powers within 60
days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise noted in the footnotes to the
following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment
power with respect to their beneficially owned Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Please see the section titled &ldquo;Plan of Distribution&rdquo;
in this prospectus for further information regarding the Selling Securityholders&rsquo; method of distributing these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Name of Selling Securityholder</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Shares<BR>
    Beneficially<BR>
    Owned <BR>
    Before<BR>
    the<BR>
    Offering<BR>
    (#)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Shares<BR>
    Being <BR>
    Offered<BR>
    (#)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Shares Beneficially<BR>
    Owned After<BR>
    the Offering(*)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(#)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(%)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 44%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">HLIP Holdings, LLC <SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">42,334,340</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">42,334,340</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Chardan Investments LP<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,948,034</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,948,034</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Ask Venture LLC<SUP>(3)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">951,330</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">951,330</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Michael Bucella<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">237,834</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">237,834</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">VA Consulting&nbsp;&amp; Advisory Inc.<SUP>(5)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">95,132</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">95,132</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Chardan Capital Markets, LLC<SUP>(6)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,853,997</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,853,997</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Avenue Venture Opportunities Fund, L.P. <SUP>(7)&nbsp;(8)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">236,049</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">140,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">96,049</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Avenue Venture Opportunities Fund II, L.P. <SUP>(7)&nbsp;(9)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">354,075</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">210,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">144,075</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1<FONT STYLE="font-size: 10pt">.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Assumes
the sale of all of the Common Stock offered in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This table and the information in this note are based upon information
supplied by the Selling Securityholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Consists of 13,692,309 shares of Common Stock issuable upon conversion
    of Series&nbsp;A Preferred Stock held by HLIP Holdings, LLC (&ldquo;HLIP&rdquo;) (formerly Hyperion DeFi Holdings, LLC), 27,384,618
    shares of Common Stock issuable upon the exercise of Purchase Warrants held by HLIP, and 1,257,413 shares of Common Stock issuable
    through the fourth quarter of 2026 as in-kind dividends on the Series&nbsp;A Preferred Stock held by HLIP at the 6% annual dividend
    rate, assuming all dividends are paid in-kind, in each case without giving effect to the beneficial ownership limitations set forth
    in the Securities Purchase Agreement, the Certificate of Designations with respect to the Series&nbsp;A Preferred Stock, or the Warrants,
    as applicable (the &ldquo;Beneficial Ownership Limitation&rdquo;).&nbsp;Pursuant to the Beneficial Ownership Limitation, HLIP is
    restricted from effecting any conversion of the Series&nbsp;A Preferred Stock or any exercise of the Purchaser Warrants which would
    result in ownership in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
    the issuance of shares of Common Stock upon such conversion or exercise. Justin Russell is the sole manager of HLIP. However, the
    amended and restated operating agreement of HLIP provides that certain disposition of the Series&nbsp;A Preferred Stock, the Purchaser
    Warrants, and the underlying shares of Common Stock require majority approval of Mr.&nbsp;Russell, Kenneth Blatt, and Mateo Levy,
    who share voting and dispositive power over the securities of the Company held by HLIP. The address of HLIP is 401 E. Jackson Street,
    Suite&nbsp;1500, Tampa, FL 33602.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Consists of 1,276,923 shares of Common Stock issuable upon conversion of Series&nbsp;A Preferred Stock held by Chardan
                                                                 Investments LP (&ldquo;ChIP&rdquo;), 2,553,846 shares of Common Stock issuable upon the exercise of Purchase Warrants held by ChIP,
                                                                 and 117,265 shares of Common Stock issuable through the fourth quarter of 2026 as in-kind dividends on the Series&nbsp;A Preferred
                                                                 Stock held by ChIP at the 6% annual dividend rate, assuming all dividends are paid in-kind, in each case without giving effect to
                                                                 the Beneficial Ownership Limitation.&nbsp;Pursuant to the Beneficial Ownership Limitation, ChIP is restricted from effecting any
                                                                 conversion of the Series&nbsp;A Preferred Stock or any exercise of the Purchaser Warrants which would result in ownership in excess
                                                                 of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
                                                                 Stock upon such conversion or exercise. The business address of ChIP is 1 Pennsylvania Plaza, Suite&nbsp;4800, New York, New York
                                                                 10119.&nbsp; ChIP is a Delaware Limited Partnership.&nbsp; Its general partner is Chardan Investments Management LLC, a Delaware
                                                                 limited liability company.&nbsp; Mr.&nbsp;Jonas Grossman is the sole manager and member of Chardan Investments Management, LLC and
                                                                 has sole voting and dispositive power over the securities of the Company held by ChIP.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD>Consists of 307,692 shares of Common Stock issuable upon conversion of Series&nbsp;A Preferred Stock held by ASK Venture LLC
                                                                                                      (&ldquo;ASK Venture&rdquo;), 615,384 shares of Common Stock issuable upon the exercise of Purchase Warrants held by ASK Venture, and
                                                                                                      28,254 shares of Common Stock issuable through the fourth quarter of 2026 as in-kind dividends on the Series&nbsp;A Preferred Stock
                                                                                                      held by ASK Venture at the 6% annual dividend rate, assuming all dividends are paid in-kind, in each case without giving effect to
                                                                                                      the Beneficial Ownership Limitation. Pursuant to the Beneficial Ownership Limitation, ASK Venture and its affiliates are restricted
                                                                                                      from effecting any conversion of the Series&nbsp;A Preferred Stock or any exercise of the Purchaser Warrants which would result in
                                                                                                      ownership in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
                                                                                                      of shares of Common Stock upon such conversion or exercise. The business address of ASK Venture is 21 Law Drive, Fairfield, NJ
                                                                                                      07004.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Consists of 76,923 shares of Common Stock issuable upon conversion of Series&nbsp;A Preferred Stock held by Michael Bucella,
                                                                 153,846 shares of Common Stock issuable upon the exercise of Purchase Warrants held by Mr.&nbsp;Bucella, and 7,065 shares of Common
                                                                 Stock issuable through the fourth quarter of 2026 as in-kind dividends on the Series&nbsp;A Preferred Stock held by
                                                                 Mr.&nbsp;Bucella at the 6% annual dividend rate, assuming all dividends are paid in-kind. Mr.&nbsp;Bucella&rsquo;s business address is 360 NW 27th Street, 8th Floor, Miami, FL, 33127.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>Consists of 30,768 shares of Common Stock issuable upon conversion of Series&nbsp;A Preferred Stock held by VA
                                                                 Consulting&nbsp;&amp; Advisory Inc. (&ldquo;VA Consulting&rdquo;), 61,536 shares of Common Stock issuable upon the exercise of
                                                                 Purchase Warrants held by VA Consulting, and 2,828 shares of Common Stock issuable through the fourth quarter of 2026 as in-kind
                                                                 dividends on the Series&nbsp;A Preferred Stock held by VA Consulting at the 6% annual dividend rate, assuming all dividends are paid in-kind. Varun Anand has sole voting and dispositive power over all
                                                                 securities of the Company held by VA Consulting. The business address of VA Consulting is 223 Bayview Fairways Drive, Thornhill,
                                                                 Ontario, Canada, L3T-2Z1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(6)</TD><TD>Consists of 923,076 shares of Common Stock issuable upon conversion of Series&nbsp;A Preferred Stock held by Chardan Capital
                                                                 Markets, LLC (&ldquo;Chardan&rdquo;), 1,846,153 shares of Common Stock issuable upon the exercise of Placement Agent Warrants held
                                                                 by Chardan, and 84,768 shares of Common Stock issuable through the fourth quarter of 2026 as in-kind dividends on the Series&nbsp;A
                                                                 Preferred Stock held by Chardan at the 6% annual dividend rate, assuming all dividends are paid in-kind, in each case without
                                                                 giving effect to the Beneficial Ownership Limitation. Pursuant to the Beneficial Ownership Limitation, Chardan is restricted from
                                                                 effecting any conversion of the Series&nbsp;A Preferred Stock or any exercise of the Placement Agent Warrants which would result in
                                                                 ownership in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
                                                                 of shares of Common Stock upon such conversion or exercise. The business address of Chardan is 1 Pennsylvania Plaza,
                                                                 Suite&nbsp;4800, New York, New York 10119. Chardan is a broker-dealer and a member of the Financial Industry Regulatory
                                                                 Authority,&nbsp;Inc. Mr.&nbsp;Kerry Propper, Mr.&nbsp;Steven Urbach and Mr.&nbsp;Jonas Grossman, are Chardan&rsquo;s Chairman, Chief
                                                                 Executive Officer and President, respectively, and are each Members and Managers of Chardan Securities LLC, which holds a
                                                                 controlling interest in Chardan. The foregoing should not be construed in and of itself as an admission by any of Mr.&nbsp;Propper,
                                                                 Mr.&nbsp;Urbach or Mr.&nbsp;Grossman as to beneficial ownership of the securities beneficially owned by Chardan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(7)</TD><TD>Avenue Venture Opportunities Fund, L.P. (&ldquo;Avenue I&rdquo;) and Avenue Venture Opportunities Fund II, L.P. (&ldquo;Avenue II&rdquo;
and, together with Avenue I, the &ldquo;Lenders&rdquo;), are each Delaware limited partnerships. Avenue Capital Management II, L.P. (&ldquo;Avenue
Capital&rdquo;) is a registered investment adviser and the manager of the Lenders. Avenue Capital has sole voting and dispositive power
over all securities of the Company held by the Lenders. The address of Avenue I and Avenue II, and each of its affiliates, is 11 West
42nd Street, 9th Floor, New York, New York 10036.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Includes 96,049 shares of Common Stock and 140,000 shares of Common
    Stock issuable upon the exercise of the Lender Warrants. Pursuant to the beneficial ownership limitation set forth in the Lender
    Warrants, Avenue I is restricted from effecting any exercise of the Lender Warrants which would result in an excess of 9.99% of the
    number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon such
    exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Includes 144,075 shares of Common Stock and 210,000 shares of Common
    Stock issuable upon the exercise of the Lender Warrants. Pursuant to the beneficial ownership limitation set forth in the Lender
    Warrants, Avenue II is restricted from effecting any exercise of the Lender Warrants which would result in an excess of 9.99% of
    the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
    such exercise.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">The Selling Securityholders and their permitted
pledgees, donees, transferees, distributees, beneficiaries or other successors in interest, may from time to time offer some or all of
the Common Stock covered by this prospectus. We will not receive any of the proceeds from such sales by the Selling Securityholders. We
will bear all fees and expenses incident to our obligation to register such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">The Selling Securityholders may, from time to
time, sell any or all of their Common Stock covered hereby on the Nasdaq or any other stock exchange, market or trading facility on which
the Common Stock is traded or in private transactions. These sales may be at fixed or negotiated prices. If the Common Stock is sold through
underwriters or broker-dealers, each Selling Securityholder will be responsible for underwriting discounts or commissions or agent&rsquo;s
commissions in connection with the Common Stock held by such Selling Securityholder. A Selling Securityholder may use any one or more
of the following methods when selling Common Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot; </FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>block
trades in which the broker-dealer will attempt to sell the Common Stock as agent, but may position and resell a portion of the block as
principal to facilitate the transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>purchases
by a broker-dealer as principal and resale by the broker-dealer for its account;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>an&nbsp;over-the-counter&nbsp;distribution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>an
exchange distribution in accordance with the rules&nbsp;of the applicable exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>privately
negotiated transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>short
sales effected after the effective date of the registration statement of which this prospectus is a part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
 &ldquo;at the market&rdquo; offerings, as defined in&nbsp;Rule&nbsp;415&nbsp;under the&nbsp;Securities Act, at negotiated prices, at prices
prevailing at the time of sale or prices related to such prevailing market prices, including sales made directly on a national securities
exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>through
trading plans entered into by the Selling Securityholders pursuant to&nbsp;Rule&nbsp;10b5-1&nbsp;under the&nbsp;Exchange Act, that are
in place at the time of an offering pursuant to this prospectus that provide for periodic sales of their securities on the basis of parameters
described in such trading plans;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>through
firm-commitment underwritten public offerings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
combination of any such methods of sale; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
other method permitted pursuant to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">The Selling Securityholders may, from time to
time, pledge or grant a security interest in some or all of the Common Stock owned by it and, if a Selling Securityholder defaults in
the performance of its secured obligations, the pledgees or secured parties may offer and sell the Common Stock, from time to time, under
this prospectus, or under an amendment to this prospectus under Rule&nbsp;424(b)(3)&nbsp;or other applicable provision of the&nbsp;Securities
Act&nbsp;amending the list of the Selling Securityholders to include the pledgee, transferee, or other successors in interest as the Selling
Securityholders under this prospectus. The Selling Securityholders also may transfer the Common Stock owned by them in other circumstances,
in which case the transferees, pledgees or other successors in interest will be the beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">In connection with the sale of the Common Stock,
or interests therein, the Selling Securityholders may enter into hedging transactions with broker-dealers or affiliates thereof or other
financial institutions, which may in turn engage in short sales of our Common Stock in the course of hedging the positions it assumes.
The Selling Securityholders may also sell Common Stock short and deliver the Common Stock to close out their short positions, or loan
or pledge the Common Stock to broker-dealers that in turn may sell these shares. The Selling Securityholders may also enter into option
or other transactions with broker-dealers or affiliates thereof or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or affiliates thereof or other financial institution of Common Stock offered
by this prospectus, which Common Stock such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented
or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">In addition, the Selling Securityholders may enter
into derivative or hedging transactions with third parties, or sell securities not covered by this prospectus to third parties in privately
negotiated transactions. In connection with such a transaction, the third parties may sell the applicable securities covered by and pursuant
to this prospectus and an applicable prospectus supplement or pricing supplement, as the case may be. If so, the third party may use securities
borrowed from Selling Securityholders or others to settle such sales and may use securities received from Selling Securityholders to close
out any related short positions. The Selling Securityholders may also loan or pledge Common Stock covered by this prospectus and an applicable
prospectus supplement to third parties, who may sell the loaned Common Stock or, in an event of default in the case of a pledge, sell
the pledged Common Stock pursuant to this prospectus and the applicable prospectus supplement or pricing supplement, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">In effecting sales, broker-dealers or agents engaged
by the Selling Securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions,
discounts or concessions from the Selling Securityholders in amounts to be negotiated immediately prior to the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">In offering the Common Stock covered by this prospectus,
the Selling Securityholders and any broker-dealers who execute sales for them may be deemed to be &ldquo;underwriters&rdquo; within the
meaning of the&nbsp;Securities Act&nbsp;in connection with such sales. Any profits realized by Selling Stockholders who are &ldquo;underwriters,&rdquo;
and the compensation of any broker-dealer who executes sales for them, may be deemed to be underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">In order to comply with the securities laws of
certain states, if applicable, the Common Stock must be sold in such jurisdictions only through registered or licensed brokers or dealers.
In addition, in certain states the Common Stock may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">We have advised the Selling Securityholders that
the anti-manipulation rules&nbsp;of&nbsp;Regulation M&nbsp;under the&nbsp;Exchange Act&nbsp;may apply to sales of Common Stock in the
market and to the activities of the Selling Securityholders and their affiliates. In addition, we will make copies of this prospectus
available to the Selling Securityholders for the purpose of satisfying the prospectus delivery requirements of the&nbsp;Securities Act.
The Selling Securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the Common Stock against
certain liabilities, including liabilities arising under the&nbsp;Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the time a particular offer of Common Stock
is made, if required, a prospectus supplement will be distributed that will set forth the number of shares of Common Stock being offered
and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any
discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to
any dealer, and the proposed selling price to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the securities registered hereunder
has been passed upon for us by Covington&nbsp;&amp; Burling LLP, Boston, Massachusetts. If legal matters are passed upon by counsel for
the underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The financial statements of Hyperion
DeFi,&nbsp;Inc. (formerly known as Eyenovia, Inc.) as of December&nbsp;31, 2024 and 2023 and for each of the two years in the period
ended December&nbsp;31, 2024, have been audited by Marcum LLP, independent registered public accounting firm, as stated in their
report, which includes an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern, which is
incorporated herein by reference. Such financial statements of Hyperion DeFi,&nbsp;Inc. (formerly known as Eyenovia, Inc.) are
incorporated in this prospectus by reference in reliance on the report of such firm given upon their authority as experts in
accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the reporting requirements of
the Exchange Act, and file annual, quarterly and current reports, proxy statements and other information with the SEC. SEC filings are
available at the SEC&rsquo;s website at www.sec.gov. This prospectus is only part of a registration statement on Form&nbsp;S-3 that we
have filed with the SEC under the Securities Act and therefore omits certain information contained in the registration statement. We have
also filed exhibits and schedules with the registration statement that are excluded from this prospectus, and you should refer to the
applicable exhibit or schedule for a complete description of any statement referring to any contract or other document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also maintain a website at www.hyperiondefi.com,
through which you can access our SEC filings. The information contained on, or that can be accessed through, our website is not a part
of this prospectus. We have included our website in this prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to
those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file
later with the SEC will automatically update and supersede this information. We filed a registration statement on Form&nbsp;S-3 under
the Securities Act, with the SEC with respect to the securities we may offer pursuant to this prospectus. This prospectus omits certain
information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including
the exhibits, for further information about us and the securities we may offer pursuant to this prospectus. Statements in this prospectus
regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily
complete and each statement is qualified in all respects by that reference. Copies of all or any part of the registration statement, including
the documents incorporated by reference or the exhibits, may be accessed on the SEC website as noted above in &ldquo;Where You Can Find
More Information.&rdquo; The documents we are incorporating by reference are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000141057825000743/eyen-20241231x10k.htm">our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2024 that we filed with the SEC on April&nbsp;15, 2025</A></FONT><FONT STYLE="font-size: 10pt">, as </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000141057825001047/eyen-20241231x10ka.htm"><FONT STYLE="font-size: 10pt">amended on April&nbsp;30, 2025</FONT></A><FONT STYLE="font-size: 10pt">;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000141057825001361/eyen-20250331x10q.htm">our Quarterly Report on Form&nbsp;10-Q for the three months ended March&nbsp;31, 2025 that we filed with the SEC on May&nbsp;19, 2025</A></FONT><FONT STYLE="font-size: 10pt">;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000141057825001740/hypd-20250630x10q.htm">our Quarterly Report on Form 10-Q for the three months ended June 30, 2025 that we filed with the SEC on August 13, 2025</A></FONT><FONT STYLE="font-size: 10pt">;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001682639/000110465925111671/hypd-20250930x10q.htm">our
    Quarterly Report on Form 10-Q for the three months ended September 30, 2025 that we filed with the SEC on November 14, 2025</A></FONT><FONT STYLE="font-size: 10pt">;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on
    Form&nbsp;8-K that we filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925004007/tm253514d1_8k.htm"><FONT STYLE="font-size: 10pt">January&nbsp;16,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925005978/tm254246d1_8k.htm"><FONT STYLE="font-size: 10pt">January&nbsp;24,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925006697/tm254557d1_8k.htm"><FONT STYLE="font-size: 10pt">January&nbsp;28,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925008090/tm254752d1_8k.htm"><FONT STYLE="font-size: 10pt">January&nbsp;31,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925016375/tm257380d1_8k.htm"><FONT STYLE="font-size: 10pt">February&nbsp;24,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925016919/tm257599d1_8k.htm"><FONT STYLE="font-size: 10pt">February&nbsp;25,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925026120/tm259898d1_8k.htm"><FONT STYLE="font-size: 10pt">March&nbsp;20,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925044223/tm2513612d1_8k.htm"><FONT STYLE="font-size: 10pt">May&nbsp;2,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925044238/tm2513849d1_8k.htm"><FONT STYLE="font-size: 10pt">May&nbsp;2,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925056679/tm2517193d1_8k.htm"><FONT STYLE="font-size: 10pt">June&nbsp;5,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925062095/tm2518559d1_8k.htm"><FONT STYLE="font-size: 10pt">June&nbsp;24,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925063687/tm2519021d1_8k.htm"><FONT STYLE="font-size: 10pt">June&nbsp;27,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925065294/tm2519676d1_8k.htm"><FONT STYLE="font-size: 10pt">July&nbsp;2,
    2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925080998/tm2523917d1_8k.htm"><FONT STYLE="font-size: 10pt">August
    21, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925088248/tm2525486d1_8k.htm"><FONT STYLE="font-size: 10pt">September
    8, 2025</FONT></A><FONT STYLE="font-size: 10pt">,</FONT> <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925092748/tm2526091d1_8k.htm"><FONT STYLE="font-size: 10pt">September
    24, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001682639/000110465925094565/tm25227454d1_8k.htm"><FONT STYLE="font-size: 10pt">September
    29, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001682639/000110465925096051/tm2527853d1_8k.htm"><FONT STYLE="font-size: 10pt">October
    2, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001682639/000110465925104662/tm2529890d1_8k.htm"><FONT STYLE="font-size: 10pt">October
    31, 2025</FONT></A><FONT STYLE="font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001682639/000110465925112968/tm2531349d1_8k.htm"><FONT STYLE="font-size: 10pt">November
    17, 2025</FONT></A><FONT STYLE="font-size: 10pt">, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465925119843/tm2533145d1_8k.htm" STYLE="-sec-extract: exhibit">December 10, 2025</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1682639/000110465926000748/tm2534601d1_8k.htm" STYLE="-sec-extract: exhibit">January 5, 2026</A> (in all cases, except for the information
    furnished under Items 2.02 or 7.01 and the exhibits furnished thereto);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our common
    stock contained in </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000141057825000743/eyen-20241231xex4d1.htm"><FONT STYLE="font-size: 10pt">Exhibit&nbsp;4.1</FONT></A>
    <FONT STYLE="font-size: 10pt">of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2024 that we filed
    with the SEC on April&nbsp;15, 2025; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">all reports and other documents subsequently filed by us pursuant to Sections
13(a), 13(c), 14 and 15(d)&nbsp;of the Exchange Act after the date of this prospectus and prior to the termination or completion of the
offering of securities under this prospectus shall be deemed to be incorporated by reference in this prospectus and to be a part hereof
from the date of filing such reports and other documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SEC file number for each of the documents listed
above is 001-38365.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, all reports and other documents filed
by us pursuant to the Exchange Act after the date of the initial registration statement and prior to effectiveness of the registration
statement shall be deemed to be incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any statement contained in this prospectus or in
a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that
is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded
will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may request, orally or in writing, a copy of
any or all of the documents incorporated herein by reference. These documents will be provided to you at no cost, by contacting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hyperion DeFi,&nbsp;Inc.<BR>
23461 S. Pointe Drive, Suite&nbsp;390<BR>
Laguna Hills, CA 92653<BR>
Attn: Corporate Secretary<BR>
(833) 393-6684</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may also access these documents on our website,
www.hyperiondefi.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We
have included our website address in this prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 50,770,667 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2521045d6_424b3img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>January 9<FONT STYLE="font-size: 10pt">,
2026</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 001 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2521045d6_424b3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2521045d6_424b3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E ,,# 2(  A$! Q$!_\0
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M=BY0YEJ>5ZYXWAUJXM+"5K9[:2XC'V"TF,K7+;AM$LF JIGDJN2>G%?1(
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%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2521045d6_424b3img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2521045d6_424b3img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T .D# 2(  A$! Q$!_\0
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910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
